Chief Operating and Business Officer · ORAMED PHARMACEUTICALS INC. (ORMP)

Joshua Hexter

FY2025 is the first fiscal year CompBrief holds for Joshua Hexter as a named executive officer of ORAMED PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,882,398

Compensation figures as of the proxy filed August 3, 2026 (DEF 14A).

Joshua Hexter compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$285,432
Bonus$218,148
Stock awards$1,299,065
Option awards$0
All other$79,753
Total$1,882,398

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed August 3, 2026, accession 0001213900-26-084609, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option100,000—$3.69
Option50,000—$10.40
Option9,000—$13.89

Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

ORAMED PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Nadav KidronPresident, Chief Executive Officer and Chairman$4,774,660
Joshua Hexter · this pageChief Operating and Business Officer$1,882,398

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ORAMED PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy